Stem cell therapy effectiveness for Heart disease/Heart Failure

1.     Stem Cell Therapy for Vasculogenesis in Patients With Severe Myocardial Ischemia

    1. Quick Summary of findings/study: Mesenchymal stem cells sourced from bone marrow demonstrated effectiveness at reducing hospital admissions for cardiovascular disease and showed to be safe long-term for patients with coronary artery disease. The stem cells were shown to develop new blood vessels in ischemic tissue.
    2. Summary for a possible patient: Stem cell therapy using cells from bone marrow can possibly be effective at reducing cardiovascular artery disease symptoms and improving health
    3. Study Participants: Ages ranged from 30-80 and included all sexes
    4. Sources


2.     Effectiveness of Stem Cell Treatment for Adults With Ischemic Cardiomyopathy (The FOCUS Study)

    1. Quick Summary of findings/study: 60 month study conducted to monitor the effectiveness of stem cells to improve heart health. Participants were separated between receiving a placebo shot and an active stem cell injection, with participants who received the stem cell injection being monitored by NOGA electromechanical cardiac mapping(essentially a device inserted via a catheter into the heart). Patients were also monitored by hospital visits/stays, electrocardiograms, blood tests and via a 24-hour Holter monitor for the last study visit. Findings showed that patients with chronic ischemic heart failure did not have clinical improvements from transendocardial injection of autologous BMCs.
    2. Summary for a possible patient: Stem cell therapy involving directly injecting stem cells from bone marrow into the wall of the heart has not shown enough proof that it can improve heart health for those with health issues involving getting blood supply to the heart
    3. Study Participants: Individuals 18 and older with significant coronary heart disease
    4. Sources


3.     Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy

    1. Quick Summary of Findings/Study: Study suggested that intracoronary stem cell transplantation can be used to improve ventricular remodeling, boost endurance and improve survival rates of patients with Dilated Cardiomyopathy. Controls for study were those that received intracoronary transplantation of human blood stem cells from plasma and those without intracoronary infusion. Participants were evaluated annually via echocardiography, a 6 minute walk test and measured plasma levels for NT-proBNP.
    2. Summary for a possible patient: Stem cell therapy using human blood stem cells from plasma injected into the heart muscles or chambers in the heart is potentially effective at reducing an enlarged heart and allow the heart to pump blood more effectively.
    3. Study Participants: Ages 18-80 years old
    4. Sources

4.    Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina (ReACT)

    1. Quick Summary of Findings/Study: Therapeutic neovascularization was observed to determine it’s effectiveness regarding cardiac tissue recovery for those with chronic intense ischemia. Autologous cells from patient bone marrow was shown to be safe for improving myocardial perfusion, reducing symptoms associated with advanced coronary artery disease and increasing patients functional capacity after other medical techniques, medicine and equipment has already been used.
    2. Summary for a possible patient: Stem cell therapy is a possible treatment for those with blood vessel issues leading to ischemia to reduce and/or eliminate symptoms
    3. Study participants: Persons age 21+ with documented coronary artery disease and class IV angina pectoris
    4. Sources:

5.     Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase I

    1. Quick Summary of Findings/Study: Study conducted to determine if intensive therapy of cholesterol lowering statin drugs plus apheresis to clean blood of low-density lipoprotein(LDL) is more effective than stating therapy alone at reducing plaque quantities in heart arteries of patients who have acute coronary syndrome (ACS). THe study also studied if the intensive therapy increased endothelial progenitor cells(EPC), which are stem cells, which reduce cardiovascular problems in patients with ACS
    2. Summary for a possible patient: Treatment involving taking cholesterol-lowering statin drugs with apheresis, removing plasma from blood, may cause your body to produce more stem cells to reduce issues with cardiovascular disease.
    3. Study participants: Ages 31+, all genders, have acute coronary syndrome
    4. Source:

6.     PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study) (PoseidonDCM)

    1. Quick Summary of Findings/Study: Study done as a safety assessment of grafted progenitor cells used to repair myocardium.
    2. Summary for a possible patient: Evidence suggests that stem cell therapy is safe to repair heart muscle tissue specifically for those with ischemic cardiomyopathy and dilated cardiomyopathy. Cardiac function significantly improved for those with dilated cardiomyopathy.
    3. Study participants: Ages 18-95, diagnosed with non-ischemic dilated cardiomyopathy, candidate for cardiac catheterization
    4. Sources:

7.     A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure

    1. Quick summary of Findings/Study: Study done to determine the safeness and efficacy of intravenous dose of ischemia-tolerant Allogeneic Mesenchymal Bone Marrow cells in patients with non-ischemic heart failure. The pilot study found that the therapy was safe, resulted in immunomodulatory effects and improved with status and functionality of patients.
    2. Summary for a possible patient: For those with heart issues not caused by a reduced blood flow, the injection of bone marrow stem cells safely resulted in a therapy that improved patients’ immune system and overall health.
    3. Study participants: Ages 18+, males & females with non-ischemic heart failure etiology
    4. Sources:



0 0 votes